Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine - PubMed (original) (raw)
Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine
M J Main et al. Mol Pharmacol. 2000 Aug.
Abstract
Retigabine is a novel anticonvulsant with an unknown mechanism of action. It has recently been reported that retigabine modulates a potassium channel current in nerve growth factor-differentiated PC12 cells (), however, to date the molecular correlate of this current has not been identified. In the present study we have examined the effects of retigabine on recombinant human KCNQ2 and KCNQ3 potassium channels, expressed either alone or in combination in Xenopus oocytes. Application of 10 microM retigabine to oocytes expressing the KCNQ2/3 heteromeric channel shifted both the activation threshold and voltage for half-activation by approximately 20 mV in the hyperpolarizing direction, leading to an increase in current amplitude at test potentials between -80 mV and +20 mV. Retigabine also had a marked effect on KCNQ current kinetics, increasing the rate of channel activation but slowing deactivation at a given test potential. Similar effects of retigabine were observed in oocytes expressing KCNQ2 alone, suggesting that KCNQ2 may be the molecular target of retigabine. Membrane potential recordings in oocytes expressing the KCNQ2/3 heteromeric channel showed that application of retigabine leads to a concentration-dependent hyperpolarization of the oocyte, from a resting potential of -63 mV under control conditions to -85 mV in the presence of 100 microM retigabine (IC(50) = 5.2 microM). In control experiments retigabine had no effect on either resting membrane potential or endogenous oocyte membrane currents. In conclusion, we have shown that retigabine acts as a KCNQ potassium channel opener. Because the heteromeric KCNQ2/3 channel has recently been reported to underlie the M-current, it is likely that M-current modulation can explain the anticonvulsant actions of retigabine in animal models of epilepsy.
Similar articles
- Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Wickenden AD, et al. Mol Pharmacol. 2000 Sep;58(3):591-600. doi: 10.1124/mol.58.3.591. Mol Pharmacol. 2000. PMID: 10953053 - Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
Tatulian L, Delmas P, Abogadie FC, Brown DA. Tatulian L, et al. J Neurosci. 2001 Aug 1;21(15):5535-45. doi: 10.1523/JNEUROSCI.21-15-05535.2001. J Neurosci. 2001. PMID: 11466425 Free PMC article. - The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits.
Rundfeldt C, Netzer R. Rundfeldt C, et al. Neurosci Lett. 2000 Mar 17;282(1-2):73-6. doi: 10.1016/s0304-3940(00)00866-1. Neurosci Lett. 2000. PMID: 10713399 - The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ, Large CH, Sankar R. Gunthorpe MJ, et al. Epilepsia. 2012 Mar;53(3):412-24. doi: 10.1111/j.1528-1167.2011.03365.x. Epub 2012 Jan 5. Epilepsia. 2012. PMID: 22220513 Review. - Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs.
Cooper EC. Cooper EC. Epilepsia. 2001;42 Suppl 5:49-54. doi: 10.1046/j.1528-1157.2001.0420s5049.x. Epilepsia. 2001. PMID: 11887968 Review.
Cited by
- Molecular Mechanisms and Structural Basis of Retigabine Analogues in Regulating KCNQ2 Channel.
Shi S, Li J, Sun F, Chen Y, Pang C, Geng Y, Qi J, Guo S, Wang X, Zhang H, Zhan Y, An H. Shi S, et al. J Membr Biol. 2020 Apr;253(2):167-181. doi: 10.1007/s00232-020-00113-6. Epub 2020 Mar 13. J Membr Biol. 2020. PMID: 32170353 - The Effects of the KCNQ Openers Retigabine and Flupirtine on Myotonia in Mammalian Skeletal Muscle Induced by a Chloride Channel Blocker.
Su TR, Zei WS, Su CC, Hsiao G, Lin MJ. Su TR, et al. Evid Based Complement Alternat Med. 2012;2012:803082. doi: 10.1155/2012/803082. Epub 2012 Mar 25. Evid Based Complement Alternat Med. 2012. PMID: 22536291 Free PMC article. - Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
Gerlach AC, Krajewski JL. Gerlach AC, et al. Pharmaceuticals (Basel). 2010 Sep 1;3(9):2884-2899. doi: 10.3390/ph3092884. Pharmaceuticals (Basel). 2010. PMID: 27713381 Free PMC article. Review. - In silico re-engineering of a neurotransmitter to activate KCNQ potassium channels in an isoform-specific manner.
Manville RW, Abbott GW. Manville RW, et al. Commun Biol. 2019 Nov 1;2:401. doi: 10.1038/s42003-019-0648-3. eCollection 2019. Commun Biol. 2019. PMID: 31701029 Free PMC article. - Central Role of Subthreshold Currents in Myotonia.
Metzger S, Dupont C, Voss AA, Rich MM. Metzger S, et al. Ann Neurol. 2020 Feb;87(2):175-183. doi: 10.1002/ana.25646. Epub 2019 Nov 27. Ann Neurol. 2020. PMID: 31725924 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases